These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38900051)

  • 1. CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis.
    Acharya S; Basar R; Daher M; Rafei H; Li P; Uprety N; Ensley E; Shanley M; Kumar B; Banerjee PP; Melo Garcia L; Lin P; Mohanty V; Kim KH; Jiang X; Pan Y; Li Y; Liu B; Nunez Cortes AK; Zhang C; Fathi M; Rezvan A; Montalvo MJ; Cha SL; Reyes-Silva F; Shrestha R; Guo X; Kundu K; Biederstädt A; Muniz-Feliciano L; Deyter GM; Kaplan M; Jiang XR; Liu E; Jain A; Roszik J; Fowlkes NW; Solis Soto LM; Raso MG; Khoury JD; Lin P; Vega F; Varadarajan N; Chen K; Marin D; Shpall EJ; Rezvani K
    Cancer Discov; 2024 Oct; 14(10):1879-1900. PubMed ID: 38900051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
    Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
    [No Abstract]   [Full Text] [Related]  

  • 3. CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7
    Zhuang X; Long EO
    Cancer Immunol Res; 2019 Jun; 7(6):939-951. PubMed ID: 31018957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.
    Kofler DM; Chmielewski M; Rappl G; Hombach A; Riet T; Schmidt A; Hombach AA; Wendtner CM; Abken H
    Mol Ther; 2011 Apr; 19(4):760-7. PubMed ID: 21326215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors.
    Nishimura CD; Corrigan D; Zheng XY; Galbo PM; Wang S; Liu Y; Wei Y; Suo L; Cui W; Mercado N; Zheng D; Zhang CC; Zang X
    Sci Adv; 2024 May; 10(19):eadk1857. PubMed ID: 38718110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
    Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
    Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
    Abbaszade Dibavar M; Soleimani M; Mohammadi MH; Zomorrod MS
    In Vitro Cell Dev Biol Anim; 2024 Apr; 60(4):321-332. PubMed ID: 38589736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
    Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.
    Sun S; Huang C; Lu M; Xu H; Yuan Y; Zhao W; Hu X; Wang B; Zhang W; Gao X; Zheng J; Su L; Zhang Q
    Cancer Immunol Res; 2023 Apr; 11(4):515-529. PubMed ID: 36689620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
    Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
    Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy.
    Pe KCS; Jewmoung S; Rad SAH; Chantarat N; Chanswangphuwana C; Tashiro H; Suppipat K; Tawinwung S
    Biomed Pharmacother; 2024 Oct; 179():117388. PubMed ID: 39243430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy.
    Wu W; Zhou Q; Masubuchi T; Shi X; Li H; Xu X; Huang M; Meng L; He X; Zhu H; Gao S; Zhang N; Jing R; Sun J; Wang H; Hui E; Wong CC; Xu C
    Cell; 2020 Aug; 182(4):855-871.e23. PubMed ID: 32730808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
    Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
    Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.